Eli Lilly and Co Stock (NYSE:LLY), Analyst Ratings, Price Targets, Predictions

The latest price target for Eli Lilly and Co (NYSE: LLY) was reported by BMO Capital on May 1, 2024. The analyst firm set a price target for $1001.00 expecting LLY to rise to within 12 months (a possible 29.07% upside). 83 analyst firms have reported ratings in the last year.

The latest analyst rating for Eli Lilly and Co (NYSE: LLY) was provided by BMO Capital, and Eli Lilly and Co maintained their outperform rating.

The last upgrade for Eli Lilly and Co happened on April 3, 2024 when Erste Group raised their price target to N/A. Erste Group previously had a hold for Eli Lilly and Co.

The last downgrade for Eli Lilly and Co happened on February 21, 2024 when DZ Bank changed their price target from N/A to $820 for Eli Lilly and Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eli Lilly and Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eli Lilly and Co was filed on May 1, 2024 so you should expect the next rating to be made available sometime around May 1, 2025.

While ratings are subjective and will change, the latest Eli Lilly and Co (LLY) rating was a maintained with a price target of $900.00 to $1001.00. The current price Eli Lilly and Co (LLY) is trading at is $775.52, which is out of the analyst’s predicted range.